Skip to content

Twist Bioscience

US · TWST #1258 by market cap Listed 2018
103.32 -8.30 -7.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 40 in the most recent period (2026/Q3).
  • Total institutional ownership rose 3.0 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
127.93% +3.03pp
Institutions
447 +40
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund104.36%
Hedge Fund14.93%
Public Company4.90%
Private Company1.66%
Government Pension Fund1.36%
Individual/Insider1.31%
Insurance Company0.54%
VC/PE Fund0.10%

Top holders as of 2026-08-31

FMR 13.97% · 8.76M sh
BlackRock 9.30% · 5.83M sh
Artisan Partners Limited Partnership 7.66% · 4.80M sh
T. Rowe Price Group, Inc. 6.75% · 4.23M sh
ARK Investment Management LLC 5.40% · 3.39M sh
State Street Global Advisors 5.15% · 3.23M sh
Vanguard Capital Management, LLC 5.01% · 3.14M sh
Vanguard Portfolio Management, LLC 4.51% · 2.82M sh
EdgePoint Investment Group Inc. 4.02% · 2.52M sh
William Blair Investment Management, LLC 3.97% · 2.49M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 0 buys · 50 sells

NameRoleStake
Emily Leproust Co-Founder, Board Chair & CEO 0.50%
Paula Green Officer 0.17%
Keith Crandell Independent Director 0.17%
Patrick Finn President 0.11%
Robert Chess Lead Independent Director 0.10%
Adam Laponis Chief Financial Officer 0.05%
Nelson Chan Independent Director 0.04%
Robert Ragusa Independent Director 0.04%
Dennis Cho Chief Legal Officer 0.03%
Katryn Blake Independent Director 0.03%
Melissa Starovasnik Independent Director 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 Emily Leproust Co-Founder, Board Chair & CEO Open Market Disposition -4,573 $135.40
2026-11-02 Robert Werner Vice President Open Market Disposition -148 $135.40
2026-11-02 Patrick Finn President Open Market Disposition -2,565 $135.40
2026-11-02 Paula Green Officer Open Market Disposition -1,007 $135.40
2026-11-02 Dennis Cho Chief Legal Officer Open Market Disposition -949 $135.40
2026-10-22 Patrick Finn President Open Market Disposition -2,245 $134.59
2026-10-08 Adam Laponis Chief Financial Officer Open Market Disposition -2,462 $156.30
2026-10-04 Emily Leproust Co-Founder, Board Chair & CEO Automatic Disposition -4,548 $200.44–207.46
2026-10-04 Emily Leproust Chairperson & CEO Intent to Sell (Form 144) -4,548 $202.15
2026-10-01 Emily Leproust Co-Founder, Board Chair & CEO Open Market Disposition -45,736 $188.88
2026-10-01 Robert Werner Vice President Open Market Disposition -1,482 $188.88
2026-10-01 Patrick Finn President Open Market Disposition -25,714 $188.88
2026-10-01 Paula Green Officer Open Market Disposition -10,088 $188.88
2026-10-01 Adam Laponis Chief Financial Officer Open Market Disposition -8,057 $188.88
2026-10-01 Dennis Cho Chief Legal Officer Open Market Disposition -9,514 $188.88
2026-09-30 Emily Leproust Co-Founder, Board Chair & CEO Automatic Disposition -655 $200.00
2026-09-23 Emily Leproust Co-Founder, Board Chair & CEO Automatic Disposition -5,203 $175.23–184.60
2026-09-20 Emily Leproust Co-Founder, Board Chair & CEO Open Market Disposition -1,687 $165.49
2026-09-20 Paula Green Officer Open Market Disposition -294 $165.49
2026-09-20 Dennis Cho Chief Legal Officer Open Market Disposition -348 $165.49

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.

Twist Bioscience discussion 0 comments

Add a comment